within Pharmacolibrary.Drugs.ATC.B;

model B03XA01_1
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 1.8333333333333333e-07,
    adminDuration  = 600,
    adminMass      = 100 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 5.8e-05,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 6.7e-05,
    k12             = 0.017,
    k21             = 0.017
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>B03XA01_1</td></tr><td>route:</td><td>subcutaneous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Erythropoietin is a glycoprotein hormone used to stimulate erythropoiesis (red blood cell production) in patients with anemia, particularly anemia associated with chronic kidney disease, chemotherapy, or certain treatments for HIV. Recombinant human erythropoietin (epoetin alfa and similar agents) is approved and widely used in clinical practice.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters of recombinant human erythropoietin (epoetin alfa) administered subcutaneously to adult healthy volunteers.</p><h4>References</h4><ol><li><p>D&#x27;Cunha, R, et al., &amp; An, G (2019). Target-mediated disposition population pharmacokinetics model of erythropoietin in premature neonates following multiple intravenous and subcutaneous dosing regimens. <i>European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences</i> 138 105013–None. DOI:<a href=\"https://doi.org/10.1016/j.ejps.2019.105013\">10.1016/j.ejps.2019.105013</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31340188/\">https://pubmed.ncbi.nlm.nih.gov/31340188</a></p></li><li><p>Jensen, JD, et al., &amp; Madsen, JK (1994). The pharmacokinetics of recombinant human erythropoietin after subcutaneous injection at different sites. <i>European journal of clinical pharmacology</i> 46(4) 333–337. DOI:<a href=\"https://doi.org/10.1007/BF00194401\">10.1007/BF00194401</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/7957518/\">https://pubmed.ncbi.nlm.nih.gov/7957518</a></p></li><li><p>Sans, T, et al., &amp; Farrè, M (2000). Pharmacokinetics of several subcutaneous doses of erythropoietin: potential implications for blood transfusion. <i>Clinical and experimental pharmacology &amp; physiology</i> 27(3) 179–184. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/10744344/\">https://pubmed.ncbi.nlm.nih.gov/10744344</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end B03XA01_1;
